Cargando…

Early Prediction Model of Gestational Hypertension by Multi-Biomarkers Before 20 Weeks Gestation

BACKGROUND: Gestational hypertension (GH), a hypertensive disorder of pregnancy (HDP), is a leading cause of maternal and fetal mortality due to the lack of clarity on its exact etiology and clinically feasible prediction models. This study was performed to discover novel biomarkers before 20 weeks...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Cheng, Song, Chunlin, Huang, Xiang, Chen, Shufen, Long, Yan, Zeng, Shanshui, Yang, Hongling, Jiang, Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8178612/
https://www.ncbi.nlm.nih.gov/pubmed/34103953
http://dx.doi.org/10.2147/DMSO.S309725
_version_ 1783703607561945088
author Zhou, Cheng
Song, Chunlin
Huang, Xiang
Chen, Shufen
Long, Yan
Zeng, Shanshui
Yang, Hongling
Jiang, Min
author_facet Zhou, Cheng
Song, Chunlin
Huang, Xiang
Chen, Shufen
Long, Yan
Zeng, Shanshui
Yang, Hongling
Jiang, Min
author_sort Zhou, Cheng
collection PubMed
description BACKGROUND: Gestational hypertension (GH), a hypertensive disorder of pregnancy (HDP), is a leading cause of maternal and fetal mortality due to the lack of clarity on its exact etiology and clinically feasible prediction models. This study was performed to discover novel biomarkers before 20 weeks gestation and thereby construct an early GH prediction model. METHODS: This study was designed based on differentially expressed protein screening followed by clinical validation. In the screening phase, a nested case-controlled study was conducted by plasma proteomic analyses using label-free LC-MS/MS and plasma samples from seven pre-GH cases before 20-week gestation and seven age- and gestational week-matched controls. In the validation phase, 10 proteins with differential expression in the screening phase were validated by ELISA or electrochemiluminescence in an independent study consisting of 29 pre-GH cases before 20-week gestation and 29 matched controls. RESULTS: In the screening phase, 149 proteins were found to be differentially expressed between the two groups and were predominantly involved in complement and coagulation cascades, platelet degranulation and positive regulation of cell motility. Further validation showed that serpin family C member 1 (SERPINC1), serpin family A member 5 (SERPINA5), complement factor H-related protein 5 (CFHR5), clusterin, cytokeratin 18 (CK18) and histidine-rich glycoprotein (HRG) levels were significantly higher in women who later developed GH compared to women with uncomplicated pregnancies (P<0.05). Binary logistic regression analysis was used to determine the combination efficacy of models for early prediction of GH. The model with a combination of SERPINC1, CK18 and HRG had a significantly better discriminatory power (AUC = 0.91, 95% CI 0.83–0.98) compared to the models with those proteins alone as independent predictors of GH. CONCLUSION: Plasma levels of SERPINC1, SERPINA5, CFHR5, clusterin, CK18 and HRG are potential novel predictive biomarkers of GH, and a prediction model using a combination of SERPINC1, CK18 and HRG has good discriminatory performance for GH before 20 weeks gestation.
format Online
Article
Text
id pubmed-8178612
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-81786122021-06-07 Early Prediction Model of Gestational Hypertension by Multi-Biomarkers Before 20 Weeks Gestation Zhou, Cheng Song, Chunlin Huang, Xiang Chen, Shufen Long, Yan Zeng, Shanshui Yang, Hongling Jiang, Min Diabetes Metab Syndr Obes Original Research BACKGROUND: Gestational hypertension (GH), a hypertensive disorder of pregnancy (HDP), is a leading cause of maternal and fetal mortality due to the lack of clarity on its exact etiology and clinically feasible prediction models. This study was performed to discover novel biomarkers before 20 weeks gestation and thereby construct an early GH prediction model. METHODS: This study was designed based on differentially expressed protein screening followed by clinical validation. In the screening phase, a nested case-controlled study was conducted by plasma proteomic analyses using label-free LC-MS/MS and plasma samples from seven pre-GH cases before 20-week gestation and seven age- and gestational week-matched controls. In the validation phase, 10 proteins with differential expression in the screening phase were validated by ELISA or electrochemiluminescence in an independent study consisting of 29 pre-GH cases before 20-week gestation and 29 matched controls. RESULTS: In the screening phase, 149 proteins were found to be differentially expressed between the two groups and were predominantly involved in complement and coagulation cascades, platelet degranulation and positive regulation of cell motility. Further validation showed that serpin family C member 1 (SERPINC1), serpin family A member 5 (SERPINA5), complement factor H-related protein 5 (CFHR5), clusterin, cytokeratin 18 (CK18) and histidine-rich glycoprotein (HRG) levels were significantly higher in women who later developed GH compared to women with uncomplicated pregnancies (P<0.05). Binary logistic regression analysis was used to determine the combination efficacy of models for early prediction of GH. The model with a combination of SERPINC1, CK18 and HRG had a significantly better discriminatory power (AUC = 0.91, 95% CI 0.83–0.98) compared to the models with those proteins alone as independent predictors of GH. CONCLUSION: Plasma levels of SERPINC1, SERPINA5, CFHR5, clusterin, CK18 and HRG are potential novel predictive biomarkers of GH, and a prediction model using a combination of SERPINC1, CK18 and HRG has good discriminatory performance for GH before 20 weeks gestation. Dove 2021-05-31 /pmc/articles/PMC8178612/ /pubmed/34103953 http://dx.doi.org/10.2147/DMSO.S309725 Text en © 2021 Zhou et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Zhou, Cheng
Song, Chunlin
Huang, Xiang
Chen, Shufen
Long, Yan
Zeng, Shanshui
Yang, Hongling
Jiang, Min
Early Prediction Model of Gestational Hypertension by Multi-Biomarkers Before 20 Weeks Gestation
title Early Prediction Model of Gestational Hypertension by Multi-Biomarkers Before 20 Weeks Gestation
title_full Early Prediction Model of Gestational Hypertension by Multi-Biomarkers Before 20 Weeks Gestation
title_fullStr Early Prediction Model of Gestational Hypertension by Multi-Biomarkers Before 20 Weeks Gestation
title_full_unstemmed Early Prediction Model of Gestational Hypertension by Multi-Biomarkers Before 20 Weeks Gestation
title_short Early Prediction Model of Gestational Hypertension by Multi-Biomarkers Before 20 Weeks Gestation
title_sort early prediction model of gestational hypertension by multi-biomarkers before 20 weeks gestation
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8178612/
https://www.ncbi.nlm.nih.gov/pubmed/34103953
http://dx.doi.org/10.2147/DMSO.S309725
work_keys_str_mv AT zhoucheng earlypredictionmodelofgestationalhypertensionbymultibiomarkersbefore20weeksgestation
AT songchunlin earlypredictionmodelofgestationalhypertensionbymultibiomarkersbefore20weeksgestation
AT huangxiang earlypredictionmodelofgestationalhypertensionbymultibiomarkersbefore20weeksgestation
AT chenshufen earlypredictionmodelofgestationalhypertensionbymultibiomarkersbefore20weeksgestation
AT longyan earlypredictionmodelofgestationalhypertensionbymultibiomarkersbefore20weeksgestation
AT zengshanshui earlypredictionmodelofgestationalhypertensionbymultibiomarkersbefore20weeksgestation
AT yanghongling earlypredictionmodelofgestationalhypertensionbymultibiomarkersbefore20weeksgestation
AT jiangmin earlypredictionmodelofgestationalhypertensionbymultibiomarkersbefore20weeksgestation